

PhD in Infectious Diseases: Cellular Biology and immunology

Abdoulaye Oury BARRY_ 20/01/1981_ Guinean

Rue du wainage 220_6240 Farciennes_Belgium

+32 (0)488 94 32 06

babdoulaye.oury@gmail.com

PROFESSIONAL EXPERIENCES

Academic Experience

04/2018- : **Volunteer work: Scientific Researcher and Trainer at LReSViS**

Laboratoire de Recherche en Sciences de la Vie et de la Santé (LReSViS), UGANC,
Guinea

2012-2017 **Chargé de Recherche in cellular and molecular biology, ULB, Belgium**

- Management of research project
- Designing and planning of experimental work
- Data processing, writing of reports and scientific articles
- Data presentation in international and lab meeting
- Coordinator and head of the mammalian cells culture platform
- Training of technician and student on how use the platform
- Team work

2009-2012 **PhD in Infectious Diseases, URMITE, Université Aix-Marseille, France**


- Head of the microscopy platform
- Management of microscope reservation planning
- Organization and planning of research works
- Work in collaboration with others researchers in the context of a scientific research

Pharmaceutical Experience

10/2017- : **CVO-Europe Consultant in qualification and validation in biopharma, Belgium**

Mission2^{ème}: IT validation, GSK (Wavre)

Mission1^{ère}: Support environmental monitoring of purified water (PW), GSK (Rixensart)



04-08 /2017: Traineeship in the QA department at Univercells, Gosselies, Belgium


- Writing of use procedures of autoclaves and incubators
- Writing of validation procedures of autoclaves and incubators
- Training in Conflict management (01 June 2017)
- Autoclave qualification
- Biosafety training (06 July 2017)

02-04/2017 Training“coordinator in qualification and validation in biopharma”Cefochim, Belgium

- Good practices in biopharma: GMP
- Project management
- SOP and documents management
- Control over contamination in sterile products manufacturing
- Audits internal and external
- Deviation management- CAPA system- Change control
- Media simulation of process
- Quality Risk Management
- Qualification and management of PW and WFI systems
- Regulatory affairs in validation
- Equipment qualification(CAAs, cold room, autoclave and biofermentor): IQ, OQ and PQ
- Validation of IT systems, analytical methods (ELISA) and cleaning procedures

TECHNICAL SKILLS

- **Cellular biology:** Intracellular trafficking of bacteria, virus, lipopolysaccharide, plasma membrane and vacuolar amino acid transporters and signaling pathways.
- **Cells culture:** BMDM, HeLa cells, HEK293T, Jurkat, yeast, lice hemocytes, bacteria
- **Molecular biology:** PCR, recombination in vitro, plasmids construction
- **Biochemistry:** Western blot, recombinants proteins production
- **Microscopy assay:** epifluorescence and confocal microscope
- **Immunofluorescence, cell transfection assays**
- **Immunology and Microbiology**



EDUCATION


- 2009-2012 **PhD in Infectious Diseases:** Aix-Marseille Université, France
- 2007-2009 **Masters: Human Pathology and Infectious Disease,** Aix-Marseille Université, France
- 2004-2007 **Bachelor of Physiology and Biological Engineering,** Université de Provence, France
- 2002-2003 **Medical study (PCEM1),** Aix-Marseille Université, France
- 2001-2002 **Medical study,** Université Gamal Abdel Nasser de Conakry, Guinea
- 2000-2001 **Biomedical study,** Université Gamal Abdel Nasser de Conakry, Guinea
-

COMPLEMENTARY INFORMATIONS

- **Languages:** French (maternal) and English
 - **Awards:** - **Silver medal (2011) for the good quality of my research work**
- **Best thesis prize (2013), URMITE**
-

SCIENTIFICS PUBLICATIONS

- 1- Barthelemy C, **Barry AO**, Twyffels L, and André B, *FTY720-induced endocytosis of yeast and human amino acid transporters is preceded by reduction of their inherent activity and TORC1 inhibition*. Scientific report, **2017 Oct 23**
- 2- Llinares E, **Barry AO**, André B, *The AP-3 adaptor complex mediates sorting of yeast and mammalian PQ-loop-family basic amino acid transporters to the vacuolar/lysosomal membrane*. Scientific report, **2015 Nov**
- 3- Bechah Y, Verneau J, Ben Amara A, **Barry AO**, Lépolard C, Achard V, Panicot-Dubois L, Textoris J, Capo C, Ghigo E, Mege JL, *Persistence of Coxiella burnetii, the Agent of Q Fever, in Murine Adipose Tissue*, PLoS One. **2014 May**
- 4- Mottola G, Boucherit N, Trouplin V, **Barry AO**, Soubeyran P, Mege JL, Ghigo E, *Tropheryma whipplei, the agent of Whipple's disease, affects the early to late phagosome transition and survives in a Rab5- and Rab7-positive compartment*, PLoS One. **2014 Feb**
- 5- Balique F, Colson P, **Barry AO**, Nappéz C, Ferretti A, Moussawi KA, Ngounga T, Lepidi H, Ghigo E, Mege JL, Lecoq H, Raoult D., *Tobacco Mosaic Virus in the Lungs of Mice following Intra-Tracheal Inoculation*, PLoS One. **2013**
- 6- **Barry AO**, Boucherit N, Mottola G, Vadovic P, Trouplin V, Soubeyran P, Capo C, Bonatti S, Nebreda A, Toman R, Lemichez E, Mege JL, Ghigo E., *Impaired Stimulation of p38 α -MAPK/Vps41-HOPS by LPS from Pathogenic Coxiella burnetii Prevents Trafficking to Microbicidal Phagolysosomes*”, Cell Host Microbe. **2012 Dec**
- 7- Boucherit N, **Barry AO**, Mottola G, Trouplin V, Capo C, Mege JL, Ghigo E. “*Effects of Coxiella burnetii on MAPKinases phosphorylation*”, FEMS Immunol Med Microbiol. 2012 Feb;64(1):101-



3. doi: 10.1111/j.1574-695X.2011.00852.x. Epub **2011 Aug 30**.
- 8- Subramanian G, **Barry AO**, Ghigo E, Raoult D, Mediannikov O “*Antibiotic susceptibility of *Diplorickettsia massiliensis**”, FEMS Immunol Med Microbiol. **2012 Feb**
- 9- **Barry AO et al.**, “*Role of the leukocyte activation in phagosome maturation process*” in *Host pathogens interaction: At the frontier of cellular Microbiology*, Edition Signpost. Edt Ghigo Eric, **2012**
- 10- **Barry AO**, Mege JL, Ghigo E., “*Hijacked phagosomes and leukocyte activation: an intimate relationship*”, J Leukoc Biol. **2011 Mar**
- 11- Ghigo E, **Barry AO**, Pretat L, Al Moussawi K, Desnues B, Capo C, Kornfeld H, Mege JL., *IL-16 Promotes T. whipplei replication by inhibiting phagosome conversion and modulating macrophage activation*, PLoS One. **2010 Oct 21**